PATENT CLAIM ANALYSIS

Application Number: 16028228
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-12
Patent Classification: ["514", "252120"]

Abstract:
The present invention provides a composition and method for treating acute on chronical liver failure or a related disease. The method comprises administering to a subject a composition comprising trimetazidine hydrochloride (1-[2,3,4-trimethoxybenzyl] piperazine dihydrochloride) (Trimetazidine or TMZ) or a pharmaceutically acceptable salt thereof according to a dosage regimen.

Claim (Index 26):
The method according to  claim 24 , wherein the formulation is structured to provide a sustained release release of 10 mg to 30 mg of TMZ every 4 to 6 hours over a period from one day to one month.

Metadata:
- Claim Count in Document: 71.0
- Percentile: 95.0
- Lexical Diversity: 1.32558
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14891746', '15092533', '11602571', '14326075', '12713497']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7111565706053335
- 35 USC 102 Novelty (BERT): 0.5122175962197044
- Combined Prediction Score: 0.6912626731667706
- Mean Citation Score: 190.156372
- Max Citation Score: 196.69803
- Similarity Product: 107.19357102477191

Labels:
- Claim Label 101: 0
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test